MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.70
+0.20
+2.35%
After Hours: 8.75 +0.05 +0.57% 19:59 06/12 EDT
OPEN
8.47
PREV CLOSE
8.50
HIGH
8.74
LOW
8.45
VOLUME
2.39M
TURNOVER
--
52 WEEK HIGH
11.23
52 WEEK LOW
6.00
MARKET CAP
2.21B
P/E (TTM)
-4.8973
1D
5D
1M
3M
1Y
5Y
1D
BioCryst Shareholders Approve Expanded Equity Incentive Plan
TipRanks · 15h ago
BioCryst shareholders approve amended stock incentive plan, add 7 million shares
PUBT · 15h ago
BioCryst Reports New Positive Data For ORLADEYO And Navenibart In Treating Hereditary Angioedema
NASDAQ · 20h ago
BioCryst to present new Orladeyo data at EAACI
TipRanks · 1d ago
BioCryst says post hoc ALPHA-STAR analysis shows navenibart cuts HAE attack rates across patient subgroups
PUBT · 1d ago
BIOCRYST PRESENTS NEW CLINICAL DATA AND REAL-WORLD EVIDENCE DEMONSTRATING IMPACT OF HAE PORTFOLIO AT THE 2026 EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY ANNUAL MEETING
Reuters · 1d ago
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
Seeking Alpha · 2d ago
BioCryst grants 9 new hires options for 33,950 shares, RSUs for 80,650 shares under inducement plan
PUBT · 3d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.